Diagnostic method for chronic myeloproliferative diseases – method for quantitatively analyzing the JAK2 genetic mutation –
Chronic myeloproliferative diseases (cMPD) are conditions in which an abnormality at the hematopoietic level is recognized, which includes polycythemia vera, essential thrombocytosis and primary myelofibrosis. In recent years, a genetic mutation known as Janus kinase 2 (JAK2) has been frequently observed in these conditions.
We have a method of quantitatively analyzing the JAK2 genetic mutation. Using a fluorescent probe, it is possible to diagnose cMPD quickly and accurately.
●It is a cMPD diagnostic tool that can accurately diagnose polycythemia vera, essential thrombocytosis and primary myelofibrosis.
●It can also be used as a tool for monitoring disease progress and treatment results.
High-sensitivity qualitative and quantitative measurement: false positives do not readily occur in clinical specimens, with the lowest limit in the quantitative determination of Allele Burden of ~5%. Homo- and heterozygous-type distinction is possible: it can accurately diagnose cMPD. Low cost, simple operation: it is possible to diagnose cMPD in one reaction by fluorescent measurement alone. High throughput: 96 – 384 samples can be measured simultaneously, and assay results obtained in two to three hours. Test samples: blood, bone, spinal fluid, etc.
purpose of providing seeds
Sponsord research, Collaboration research, Technical consultation
same researcher's seeds